DK2294215T3 - Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder - Google Patents

Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder

Info

Publication number
DK2294215T3
DK2294215T3 DK09747388.8T DK09747388T DK2294215T3 DK 2294215 T3 DK2294215 T3 DK 2294215T3 DK 09747388 T DK09747388 T DK 09747388T DK 2294215 T3 DK2294215 T3 DK 2294215T3
Authority
DK
Denmark
Prior art keywords
tests
response
cancer patients
treatment options
chemotherapeutic treatment
Prior art date
Application number
DK09747388.8T
Other languages
English (en)
Inventor
Steve Shak
Joffre B Baker
Carl Yoshizawa
Joseph Sparano
Robert Gray
Original Assignee
Genomic Health Inc
Aventis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc, Aventis Inc filed Critical Genomic Health Inc
Application granted granted Critical
Publication of DK2294215T3 publication Critical patent/DK2294215T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK09747388.8T 2008-05-12 2009-05-12 Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder DK2294215T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5257308P 2008-05-12 2008-05-12
US5718208P 2008-05-29 2008-05-29
PCT/US2009/043667 WO2009140304A1 (en) 2008-05-12 2009-05-12 Tests to predict responsiveness of cancer patients to chemotherapy treatment options

Publications (1)

Publication Number Publication Date
DK2294215T3 true DK2294215T3 (da) 2013-04-22

Family

ID=41319028

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09747388.8T DK2294215T3 (da) 2008-05-12 2009-05-12 Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
DK12195318.6T DK2568053T3 (da) 2008-05-12 2009-05-12 Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12195318.6T DK2568053T3 (da) 2008-05-12 2009-05-12 Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder

Country Status (6)

Country Link
US (1) US20090311702A1 (da)
EP (5) EP2294215B1 (da)
CA (1) CA2723972A1 (da)
DK (2) DK2294215T3 (da)
ES (2) ES2482692T3 (da)
WO (1) WO2009140304A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374311T3 (es) * 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
HUE050365T2 (hu) 2003-06-24 2022-09-28 Genomic Health Inc Rákkiújulás valószínûségének elõrejelzése
ES2636470T3 (es) 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2010045318A2 (en) * 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
WO2011060537A1 (en) 2009-11-20 2011-05-26 The Governors Of The University Of Alberta Predictive markers for taxane responsiveness and methods of use thereof
MX337650B (es) * 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.
WO2011075724A2 (en) * 2009-12-18 2011-06-23 The University Of North Carolina At Chapel Hill Methods and compositions for analysis of clear cell renal cell carcinoma
US20130011393A1 (en) * 2010-01-12 2013-01-10 Johnathan Mark Lancaster Bad pathway gene signature
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
WO2012097276A2 (en) * 2011-01-13 2012-07-19 Expression Pathology, Inc. Bcl-2-like protein 11 srm/mrm assay
EP2699237A4 (en) 2011-04-21 2014-11-12 Childrens Hosp Medical Center THERAPY FOR LEUKEMIA
US10342767B2 (en) 2011-04-21 2019-07-09 Children's Hospital Medical Center Therapy for kinase-dependent malignancies
CN102312002A (zh) * 2011-09-20 2012-01-11 李艳 一种快速检测BRCA1基因mRNA表达量的试剂盒
WO2013130465A2 (en) * 2012-02-27 2013-09-06 Genomic Health, Inc. Gene expression markers for prediction of efficacy of platinum-based chemotherapy drugs
WO2013170174A1 (en) 2012-05-10 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing, treating and determining progression and survival of cancer cells using bcl-2 antagonist of cell death (bad) pathway gene signature
CN102965433A (zh) * 2012-09-29 2013-03-13 李艳 一种检测M BCR融合基因mRNA表达量的试剂盒
CA2891653A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2014092572A1 (en) * 2012-12-12 2014-06-19 Universiteit Leiden Improved methods for cancer treatment with a genotoxic agent
SG11201510816SA (en) * 2013-07-03 2016-01-28 Hoffmann La Roche Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
BR112016022499A2 (pt) * 2014-04-03 2017-08-15 Invictus Oncology Pvt Ltd Produtos terapêuticos combinatórios supramoleculares
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2015187496A1 (en) * 2014-06-02 2015-12-10 Children's Hospital Medical Center Therapy for solid tumors
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
US11136583B2 (en) 2017-01-10 2021-10-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2019217581A2 (en) * 2018-05-11 2019-11-14 Baylor College Of Medicine Mutl loss predicts sensitivity to cdk4/6 inhibitors in cancer
US20210317535A1 (en) * 2018-08-29 2021-10-14 The Regents Of The University Of Michigan Methods of determining treatment consisting of radiation therapy and/or alkylating chemotherapy in patients suffering from cancer
CN109439755A (zh) * 2018-11-30 2019-03-08 广东腾飞基因科技股份有限公司 一种用于检测乳腺癌相关基因表达水平的试剂盒
US12353987B1 (en) 2024-06-20 2025-07-08 DDAIM Inc. Modular SoC AI/ML inference engine with dynamic updates using a hub-and-spoke topology at each neural network layer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627733B2 (en) * 1993-06-14 2003-09-30 Jeffrey D. Johnson Receptor tyrosine kinase with a discoidin-type binding domain
JP2000038909A (ja) 1998-07-22 2000-02-08 Mitsubishi Electric Corp バルブタイミング可変装置
AU3118602A (en) 2000-10-18 2002-04-29 Genomic Health Inc Genomic profile information systems and methods
ES2374311T3 (es) 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
AU2004248120B2 (en) * 2003-05-28 2009-04-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
HUE050365T2 (hu) 2003-06-24 2022-09-28 Genomic Health Inc Rákkiújulás valószínûségének elõrejelzése
AU2004258085B2 (en) 2003-07-10 2010-05-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
CA2542656A1 (en) 2003-10-16 2005-05-06 Genomic Health, Inc. Qrt-pcr assay system for gene expression profiling
FR2863275B1 (fr) * 2003-12-09 2007-08-10 Biomerieux Sa Procede pour le diagnostic/pronostic du cancer du sein
ES2636470T3 (es) * 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2007057746A2 (en) * 2005-05-27 2007-05-24 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing chemotherapeutic drug resistance in a cancer cell
ES2624863T3 (es) * 2005-06-08 2017-07-17 Millennium Pharmaceuticals, Inc. Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007028146A2 (en) * 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
EP2228457A1 (en) * 2007-08-16 2010-09-15 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy

Also Published As

Publication number Publication date
EP2568053B1 (en) 2014-04-16
US20090311702A1 (en) 2009-12-17
CA2723972A1 (en) 2009-11-19
DK2568053T3 (da) 2014-07-21
WO2009140304A1 (en) 2009-11-19
EP2294215A4 (en) 2011-06-29
EP2641977A1 (en) 2013-09-25
EP2607497A1 (en) 2013-06-26
EP2607497B1 (en) 2014-10-01
HK1180727A1 (en) 2013-10-25
ES2403220T3 (es) 2013-05-16
EP2294215B1 (en) 2013-01-16
EP2641977B1 (en) 2014-09-03
EP2641978A1 (en) 2013-09-25
ES2482692T3 (es) 2014-08-04
EP2294215A1 (en) 2011-03-16
HK1154910A1 (en) 2012-05-04
EP2568053A1 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
DK2294215T3 (da) Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
DK3431115T3 (da) Kateterindretning
EP2138200A4 (en) SUCTION CATHETER OF A THROMBUS
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
EP3329912C0 (en) LIQUID COMPOSITION
DK3289876T3 (da) Forbindelser til behandling af cancer
BRPI0718313A2 (pt) Conjunto de cateter
EP2213325A4 (en) CATHETER
DK2789349T3 (da) Flydende præparat omfattende pimobendan
EP2129285A4 (en) Analyte sensor
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
DE602007000495D1 (de) Flüssigkeit-Koinfusionsgerät
EP2110789A4 (en) PAPER MONEY PROCESSOR
EP2216067A4 (en) CATHETER
DK3211005T3 (da) Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2118174T3 (da) Anvendelse af tocopherol
DK3388111T3 (da) Organoarsenforbindelse til behandlingen af kræft
DK3326681T3 (da) Indretning til behandling af analsphincteren
EP2142466A4 (en) ULTRADUNE MAGNESIUM NANOBLATTERS
FR2914569B1 (fr) Sorbonne de laboratoire
FR2901237B1 (fr) Vetement de sauvetage
EP2291383A4 (en) NEW CLASSES OF GABAA / BZR LIGANDS